Nuclear Medicine: Page 273

VisEn launches imaging agent

By AuntMinnie.com staff writers

Optical imaging developer VisEn Medical has launched its new Cat B 680 FAST imaging agent to measure and monitor cathepsin B activity associated with disease progression and therapeutic response in vivo.

January 18, 2010

Chalk River restart may be delayed

By AuntMinnie.com staff writers

The restart of Atomic Energy of Canada's National Research Universal nuclear reactor in Chalk River, Ontario, may be delayed until April.

January 14, 2010

Analysis favors coronary CTA over stress MPS for chest pain

By Eric Barnes

In most chest pain patients, coronary CT angiography (CTA) surpasses its rival -- stress myocardial perfusion scintigraphy (MPS) -- for diagnosing coronary artery disease, according to the results of a new model analysis comparing the two techniques.

January 14, 2010

DOPA-PET/CT can alter therapy for neuroendocrine tumors

By Wayne Forrest

Swiss researchers have found that combined fluorine-18 dihydroxyphenylalanine (F-18 DOPA) contrast-enhanced PET/CT is "significantly superior" to DOPA-PET and contrast-enhanced CT in detecting neuroendocrine tumors.

January 14, 2010

FDG-PET distinguishes Parkinson's from other disorders

By Wayne Forrest

With the help of FDG-PET, researchers in New York have developed an automated image-based classification procedure to differentiate patients with idiopathic Parkinson's disease from those with other brain diseases such as multiple system atrophy and progressive supranuclear palsy.

January 10, 2010

PET/CT finds brain-disorder-related cancer other modalities miss

By Wayne Forrest

In patents with suspected paraneoplastic neurological disorders, PET/CT is "very helpful" in detecting cancer as the cause of the condition when other imaging modalities and clinical exams find no evidence of cancer, according to an article published online January 11 in the Archives of Neurology.

January 10, 2010